KT3-671, an angiotensin AT1 receptor antagonist, attenuates vascular but not cardiac responses to sympathetic nerve stimulation in pithed rats

Journal of Cardiovascular Pharmacology
Y TakataH Kato


Effects of KT3-671 on vascular and cardiac sympathetic neurotransmission were investigated in pithed rats. The pressor response to spinal stimulation (5 Hz) of the pithed rat without the adrenals was approximately 75% of that with the adrenals. Guanethidine (8 mg/kg, i.v.) decreased by about 76% the pressor response to sympathetic stimulation in the pithed rat with intact adrenals and the guanethidine-resistant response was almost completely abolished by bilateral adrenalectomy. Therefore, the following experiments were done using the pithed rat without the adrenals. KT3-671 (1-10 mg/kg, i.v.) as well as losartan (1-10 mg/kg, i.v.) inhibited dose-dependently the pressor response to sympathetic stimulation. KT3-671 was approximately four times more potent than losartan in inhibiting the pressor response. The two angiotensin II subtype 1 receptor antagonists (10 mg/kg, i.v.) did not affect the pressor response to exogenously administered norepinephrine. Neither KT3-671 nor losartan influenced the tachycardia induced by spinal stimulation and isoprenaline. Intravenous infusion of angiotensin II (100 ng/kg/min) did not affect both pressor and tachycardic responses to sympathetic stimulation. In conclusion, KT3-671 as well as losart...Continue Reading


Jul 1, 1986·The Journal of Clinical Investigation·D J Campbell, J F Habener
Jan 1, 1987·The Journal of Clinical Investigation·D J Campbell
Jan 1, 1987·Clinical and Experimental Hypertension. Part A, Theory and Practice·R R VollmerV S Murthy
Jun 1, 1985·Journal of Hypertension·D J Campbell
Dec 15, 1969·Experientia·M RothY Piquilloud
Oct 1, 1971·Biochimica Et Biophysica Acta·D W Cushman, H S Cheung
Dec 1, 1984·Journal of Hypertension·B G ZimmermanP C Wong
Jan 1, 1982·Journal of Cardiovascular Pharmacology·R Hatton, D P Clough
Jan 1, 1984·Clinical and Experimental Hypertension. Part A, Theory and Practice·R R VollmerV S Murthy
Sep 1, 1983·Hypertension·M LoudonJ D Swales
Nov 1, 1981·Hypertension·M J AntonaccioD Kotler
Jul 1, 1993·Journal of Cardiovascular Pharmacology·N MoreauJ F Giudicelli
Jan 1, 1995·Journal of Cardiovascular Pharmacology·S MochizukiA Tomiyama
Jan 1, 1994·British Journal of Pharmacology·A HilditchM J Robertson
Feb 17, 2000·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Y TakataH Kato
Mar 1, 1964·The Journal of Experimental Medicine·A B GOULDJ R KAHN

❮ Previous
Next ❯


Dec 4, 2003·British Journal of Clinical Pharmacology·D PattersonT MacDonald
Oct 13, 2012·The Journal of Pharmacy and Pharmacology·Amira M SenbelTahia T Daabees
Jul 24, 2004·Journal of Pharmacological Sciences·Yoshinobu TakataHitoshi Kato
Aug 4, 2015·Autonomic Neuroscience : Basic & Clinical·Sae UchidaHarumi Hotta

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.